Method of conservative treatment of osteochondrosis

FIELD: medicine.

SUBSTANCE: method includes introducing vitamin B12. According to the invention, vitamin B12 is administered with 0.5% novocaine in the interstitial spaces to a depth up to the yellow ligament at a dose of 500 μg/ml.

EFFECT: use of the invention makes it possible to accelerate and prolong analgesia by introducing into the depth to the yellow ligament.

1 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical compositions for the combined therapy of arthropathies, except for rheumatoid arthritis, degenerative disk diseases, joint pains and/or autoimmune disease (particularly alopecia, neurodermitis). There are presented: a pharmaceutical composition for the above application containing a glucocorticoid, exosomes prepared of autologous blood and a cytokine antagonist ortokin or anakinra; a method for producing it involving the pharmaceutical composition containing the exosomes prepared of autologous blood and the cytokine antagonist ortokin or anakinra, and the pharmaceutical composition containing the glucocorticoid and the cytokine antagonist ortokin or anakinra, and versions of using the above substances for producing the pharmaceutical composition for the combined therapy.

EFFECT: technical effect consists in achieving the synergetic effect both on the exposure rate and remote outcomes of the specified diseases with reducing side effects of the glucocorticoid (cortisone).

33 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: Alloplant dispersed biomaterial dissolved in normal saline is introduced in an amount of 10-20 ml per one injection into a space between paraspinal muscles and the neural spine or the intertransverse ligament. Each injection of the biomaterial is immediately followed by introducing normal saline in an amount of 20-100 ml to generate eccentric discomfort or pain and to produce a supplementary pressure making the biomaterial advancing along hydraulically extended intertissue, perineural and paravascular spaces to an involvement region. Thereafter, the patient is placed pronated for 12-24 hours to ensure the gravity distribution of the solution to the anterior spine. The treatment involves a therapeutic course of 3-5 one- or two-side injections of the biomaterial followed by introducing normal saline after each injection of the biomaterial every 8-12 days.

EFFECT: invention enables restoring the involved intervertebral disks with performing no traumatic operation relieving a disk radicular conflict.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to a pharmaceutical composition in the form of a soft dosage form for treating locomotor disorders, possessing anti-inflammatory, anaesthetic and anti-oedematous action, containing a combination of heparin sodium salt, dexpanthenol, diethylene glycol monoethyl ether and/or dimethylsulphoxide and target additives. The latter are presented by a gelation agent, a solvent/a solubiliser, a neutraliser, a flavouring agent/a moistening agent and water. The invention also discloses a method for producing the pharmaceutical composition.

EFFECT: reducing side actions, particularly allergic responses; it is characterised by high pharmacological activity, and simplified method for producing.

15 cl, 5 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating joint and bone tissue diseases contains a combination of active substances consisting of the glucosamine sulphate salt, chondroitin sulphate sodium salt, ibuprofen as a non-steroidal anti-inflammatory agent, additives from excipients and processing additives, wherein the additives optionally contain vitamins and a calcium-containing excipient. The group of inventions also concerns a method for preparing the above pharmaceutical composition.

EFFECT: enhancing the therapeutic effect of the pharmaceutical composition in relation to the common knowledge without increasing the number and severity of its side effects.

8 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: dispersed biomaterial Alloplant dissolved in physiological saline in ratio of biomaterial 50 mg to physiological saline 20-60 ml is injected into the involved soft tissues to provide its uniform distribution taking into account neurovascular topography into the thickness of the involved soft tissues. The treatment involves a course of 1-5 injection procedures of 5-60 ml of the biomaterial every 8-12 procedures.

EFFECT: invention enables providing higher clinical effectiveness in degenerative-dystrophic, inflammatory-degenerative diseases and traumatic injuries of locomotor soft tissues by direct and prolonged action of the regenerative material Alloplant.

6 cl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to orthopaedics, and can be used for producing a transplant for long bone tissue repair. That is ensured by collecting bone marrow aspirate into lithium heparin test tubes, diluting with phosphate salt buffer, filtered through a filter with pore size 70 mcm and centrifuging for 10 min at 400 g. That is followed by inoculating flasks 150 cm2 with the produced mesenchymal stem cells (MSCs) at 1×106 cells/cm2, culturing at temperature 37°C and 5% CO2 in air, in the Dulbecco's Modified Eagle's medium containing glucose 1 g/l and less, with 10% embryo calve serum. The medium is changed every 3 days. Before preparing the transplant, the cells are removed from the substrate with 0.05% trypsin EDTA, washed and re-suspended. The cell suspension is applied on the matrix, incubated for 3 hours at temperature 37°C with rocking in a rotation shaker at 25 rpm. The matrix is filled with the DMEM medium with 10% bovine foetal serum, dexamethasone 10-7 M, β-glycerophosphate 10 mM, ascorbate-2-phosphate 0.05 mM, 1% streptomycin 100 mcg/ml or penicillin 100 units/ml. The MSCs are cultured for 28 days. What is also presented is a method for long bone tissue repair.

EFFECT: group of inventions provides the uniform bone tissue repair in replacing the bone tissue defect of critical size with the transplant.

3 cl, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and represents a controlled-release preparative form of diacerein administered once a day for treating or autoimmune diseases or their complications. The preparative form contains a core, an active layer, a sustained-release film layer and a delayed-release film layer, wherein the active layer is followed by the sustained-release film, and the delayed-release film layer thereafter. The sustained-release film layer contains ethyl cellulose polymer, povidone, triethylacetate and talc; the delayed-release film layer contains Eudragit polymer, triethylacetate and talc.

EFFECT: reducing the negative side action of diacerein.

18 cl, 23 ex, 33 tbl

FIELD: medicine.

SUBSTANCE: non-invasive treatment of Dupuytren's contracture of degree III-IV is ensured by injecting Collalysin dissolved in 2% Novocaine into a subcutaneous fold or nodes in a projection of fetlock, proximal digital joints and/or into a fold base; 24 hours later, the fold is separated from the skin subcutaneously; the skin is mobilised, and the involved finger (fingers) are redressed.

EFFECT: invention enables the non-invasion recovery of the complete motion function of the fingers.

4 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biochemistry, in particular to single variable domain, aimed against IL-6R, to polypeptide and construction, directed against IL-6R, containing said single variable domain, as well as to methods of obtaining them. Disclosed are nucleic acids, coding said single variable domain, polypeptide and construction, as well as genetic constructions, containing said nucleic acids. Described are host cells and host organisms, containing said nucleic acids. Invention also deals with composition for blocking interaction of IL-6/IL-6R, containing effective quantity of described single variable domain, polypeptide, construction, nucleic acid or genetic construction. Also disclosed is method of prevention and/or treatment of at least one of diseases or disorders, associated with IL-6, IL-6R, complex IL-6/IL-6R and/or signal pathways, in which IL-6, IL-6R or complex IL-6/IL-6R is involved and/or biological functions and reactions, win which IL-6, IL-6R or complex IL-6/IL-6R takes part with application of described single variable domain, polypeptide, construction or composition.

EFFECT: invention makes it possible to block interaction of IL-6/IL-6R effectively with increased affinity and biological activity.

25 cl, 70 dwg, 56 tbl, 61 ex

FIELD: medicine.

SUBSTANCE: method for integrated treatment of hip diseases accompanying a total replacement involves a postoperative background therapy with using an infusion therapy, an antibiotic therapy, an anticoagulant therapy, therapeutic exercises and a physical therapy; aqueous herbal tea containing willow bark, common St.-John's wort herb, balm lemon herb, liquorice root, meadowsweet herb, mountain ash fruit, raspberry leaves taken in certain proportions 14 days before the operation and for three postoperative months in a dose of 0.5 glass 4 times a day half an hour before a meal.

EFFECT: method enables providing the higher effectiveness of the surgical management of hip diseases by improving patient's rehabilitation, promotes reducing trait and state anxieties, a rate of administration of analgesic preparations, improving the motor function of limbs and preventing postoperative complications.

1 tbl, 1 ex

FIELD: pharmacology.

SUBSTANCE: invention relates to pharmaceutical composition, possessing GABA-ergic activity, which contains 4[(4'-nicotinoylamino)butyroylamino]butanic acid, nicotinoyl gamma-aminobutyric acid, calcium salt of homopantothenic acid, thiamine chloride (vitamin B1), riboflavin (vitamin B2), pyridoxine (vitamin B6), nicotinic acid (vitamin B3), nicotinamide (vitamin B3*) calcium pantothenate (B5), folic acid (vitamin B9), cyancobalamine (vitamin B12) and as additional substances talc, calcium stearate, magnesium stearate, starch-sugar granulate, or microcrystalline cellulose, or lactose, where vitamin B1 is present in form of double granulate with polyvinylpyrrolidone and starch-sugar paste.

EFFECT: composition improvement.

5 cl, 3 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: 10-day conventional drug therapy comprising a daily vascular therapy by intravenous drop-by-drop administration of Trental 5 ml dissolved in 0.9% normal saline 200 ml is followed by a local therapeutic exposure on the involved shoulder joint. That is ensured by intramuscular administration of a therapeutic mixture containing Depot-Medrol 1 ml - 40 mg, 2% lidocaine hydrochloride 6 ml - 120 mg and cyanocobalamine 3 ml - 1.5 ml into trigger areas of supraspinous, infraspinous, deltoid and subscapular muscles. Administering the therapeutic mixture follow the schedule: on the first therapeutic day, the therapeutic mixture is injected into the trigger areas of supraspinous and infraspinous muscles in an amount of 5 ml into each muscle once a day; on the second therapeutic day, the therapeutic mixture is injected into the trigger areas of deltoid and subscapular muscles in an amount of 5 ml into each muscle once a day; from the third to ninth therapeutic day, the therapeutic mixture is introduced in a dose of 10 ml every second day into the trigger areas of the subscapular muscle.

EFFECT: method enables increasing the clinical effectiveness in the patients with scapulohumeral periarthrosis by recovering the shoulder joint function with reducing the recurrent pain syndrome considerably.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating proximal humeral injuries. That is ensured by three-staged complex therapeutic actions. At the first stage, setting of fracture and reduction of humeral head dislocation is followed by immobilising an extremity by continuous twenty-four hour brace fixation of the proximal humerus with Desault's bandage for the period of 4 weeks. From the first therapeutic day, the patient does daily 30-minute therapeutic exercises, including isometric, static and ideomotor exercises to strengthen his/her arm muscles and to improve the circulation. That is combined with a complex reparative drug therapy. At the first stage, the anti-inflammatory preparation Arthrofoon is administered orally, while vasodilators improving nicotinic acid, trental or complamin microcirculation are injected intramuscularly daily for 10 days. The enzymatic preparations Wobenzyme or Flogenzyme are also administered in a dose of 3 tablets three times a day for 3-4 weeks. The second stage starting two weeks after the beginning of the treatment involves electric stimulation (ES) by exposing the collar and shoulder muscles from the involved side for 30 minutes to electric signals generated by an electric myostimulation device. The ES procedure requires the patient to perform 15-minute active motions by a healthy arm, and for the following 15 minutes the patient is expected to tense and relax alternatively the muscles from involved side. The therapeutic exercises are also done. The drug treatment regimen of the second stage implies administering the preparations Calcemin or Calcemin Advance for six months. That is combined with 10 daily intramuscular injections of the preparation Milgamma 2 ml. At the third stage 4 weeks after the beginning of the treatment, control X-ray imaging is followed by removing the brace. Accompanied by the reparative drug therapy continued, the complex therapeutic actions provide local injection therapy in number of 8-10 daily procedures. The biologically active reflex areas nearby the involved joint are pre-exposed to focused red laser light, and the mixed preparations Alflutop, or other chondroprotector, vitamin B12, Contrykal or Lidase, Lidocaine are injected in the same areas. Two weeks after the brace has been taken off, the patient keeps doing the therapeutic exercises twice a week continuously. The drug therapy and local injections are repeated six months later. The brace is further required for the following year if the patient is supposed to bear occupational or sports physical loads.

EFFECT: method provides faster recovery of the extremity functionality, prevents posttraumatic degenerative process in the humeral joint, recurred dislocation formation, humeral instability and contractures by optimising the humeral para-articular tissue health, improving the quality of bone tissues, first of all, of the subchondral plate and humeral head.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating joint and bone tissue diseases contains a combination of active substances consisting of the glucosamine sulphate salt, chondroitin sulphate sodium salt, ibuprofen as a non-steroidal anti-inflammatory agent, additives from excipients and processing additives, wherein the additives optionally contain vitamins and a calcium-containing excipient. The group of inventions also concerns a method for preparing the above pharmaceutical composition.

EFFECT: enhancing the therapeutic effect of the pharmaceutical composition in relation to the common knowledge without increasing the number and severity of its side effects.

8 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be used for the treatment of chronic constipation and functional anorexia. For this purpose, as medicinal nutrition used is a milk-vitamin mixture with the following composition (g per 100 g of the product): Proteins 24-26, Fats 27-29, Carbohydrates 33-34, minerals (mg per 100 g of the product), calcium 940-970, phosphorus 780-820, sodium 230-270, potassium 1370-1550, chloride 1270-1350, magnesium 100-125, iron 9.5-10.7, zinc 2.7-3.5, iodine 145-173, copper 76-87, manganese 45-52, vitamins (mcg per 100 g of the product) D3 7.6-8.2, E 6.2-6.8, C 42-46, B1 960-990, B2 1150-1250, Niacin11-15, B6 1370-1440, Folic acid 125-150, Pantothenic acid 2250-2370, B12 1.5-1.9, Biotin 25-31, Choline 40-45.

EFFECT: invention provides an increase of treatment efficiency.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science and aims at treating and preventing alimentary anaemia in young pigs. A preparation contains an iron dextran complex, nanosized and zero-valent selenium (Se0), vitamin E, vitamin B12 and water in the following proportions, wt %: iron dextran complex 0.0001-80.0, selenium (Se0) 0.0001-5.0, vitamin E 0.0001-20.0, vitamin B12 0.0001-10.0, water for injections - the rest.

EFFECT: using the declared method provides compensating iron deficiency in young pigs, improving animal's growth and development, increasing total immunity and rapid adaptation to the varying ambient environment.

4 tbl, 4 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention relates to nutritive therapy and is intended for treatment and/or prevention of delayed recall function impairment in subjects who have 24-26 points by Mini-mental State Examination (MMSE). Claimed is application of composition for obtaining product for enteral introduction. Composition contains uridine or uridine phosphate, docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA), phospholipids, choline, vitamin E, vitamin C, selenium, vitamin B12, vitamin B6 and folic acid.

EFFECT: claimed invention provides improvement of memory, in particular, delayed recall function, in patients with 24-26 points by MMSE.

5 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition contains a combination of dalargin in an amount of 0.1-4 mg and vitamin specified in B1 (thiamine hydrochloride or thiamine bromide) or vitamin B6 (pyridoxine hydrochloride) or a mixture thereof in an amount of 25-100 mg.

EFFECT: composition manifests higher efficacy.

4 cl, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used for treating luetic optic neuropathy. That is ensured by subconjunctival administration of Cefazolin 0.3-0.5 mg. That is combined with intramuscular injection of Gliatilin 2.0-4.9 ml, 1-3% Glutoxim 2.0 ml and Milgamma 1.0-2.0 ml. Dexazon 0.5 ml is introduced parabulbarly. The preparations are introduced once a day for 10 days. Additionally, starting with the first therapeutic day, 10 sessions of percutaneous transcranial magnetic stimulation of the optic nerves are conducted daily.

EFFECT: method provides improving the visual functions and eliminating the complications of the central nervous system due to the integrated treatment developed with the severity of the pathological process in these patients.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely - to therapy, reflexotherapy. Method includes pharmacopuncture by injection introduction of 0.3-1 ml of drug Laennek or 0.3-1 ml of Laennek drug in combination with vitamin B 1 solution in concentration 10-25 mg/ml and vitamin B 12 solution in concentration 100-500 mcg/ml. For this purpose 1 ml of vitamin B 1 solution or 1 ml of B 12 vitamin solution is taken per 10 ml of Laennek drug for injections. Pharmacopuncture is carried out on biologically active points (BAP) VB 20, V 11, V 18, V 23, GI 10, E 36 and by BAP, selected from VB21,VB 14, VB 15, VB 34, VI, V2, E6, E 7, E 5, V 10, V 15, V 18, V 19, V 22, V 25, TR 14, Gl 11. Procedure is carried out for 20-40 minutes, 2 times per week, for from 1 to 1.5 month period.

EFFECT: method increases organism rehabilitation efficiency by reduction of pathological condition manifestations, performs prevention of ageing due to increase of skin regeneration and biorevitalisation.

3 cl, 10 dwg, 7 tbl, 14 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

Up!